Shanghai Haohai Biological Technology Co., Ltd. (FRA:5HB)
Germany · Delayed Price · Currency is EUR 2.740
+0.020 (0.74%)
At close: Jan 23, 2026
FRA:5HB Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 2,504 | 2,680 | 2,635 | 2,103 | 1,750 | 1,324 | |
Revenue Growth (YoY) | -8.21% | 1.70% | 25.27% | 20.19% | 32.14% | -16.99% |
Cost of Revenue | 791.69 | 843.12 | 788.14 | 656.52 | 490.37 | 334 |
Gross Profit | 1,712 | 1,837 | 1,847 | 1,447 | 1,260 | 990.42 |
Selling, General & Admin | 1,232 | 1,228 | 1,237 | 1,085 | 898.43 | 772.49 |
Research & Development | 199.89 | 238.93 | 220.1 | 182.19 | 167.6 | 126.47 |
Other Operating Expenses | 16.06 | -2.23 | -1.97 | 15.52 | -3.18 | -1.37 |
Operating Expenses | 1,450 | 1,465 | 1,455 | 1,283 | 1,063 | 897.59 |
Operating Income | 262.6 | 372.03 | 391.79 | 164.38 | 196.9 | 92.83 |
Interest Expense | -17.46 | -18.06 | -7.3 | -7.6 | -4.96 | -4.91 |
Interest & Investment Income | 70.86 | 73.98 | 78.15 | 88.56 | 155.75 | 144.57 |
Earnings From Equity Investments | 0.99 | 0.99 | 0.46 | 3.51 | 2.19 | -0.13 |
Other Non Operating Income (Expenses) | 77.68 | 61.88 | 44.53 | -13.3 | 32.77 | 24.66 |
EBT Excluding Unusual Items | 394.67 | 490.81 | 507.63 | 235.54 | 382.65 | 257.03 |
Gain (Loss) on Sale of Investments | 0.43 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.2 | - | 0.63 | 0.19 | - | - |
Legal Settlements | -27.6 | -27.6 | - | - | - | - |
Other Unusual Items | 58.96 | 2.94 | - | - | - | - |
Pretax Income | 425.21 | 466.15 | 508.26 | 235.73 | 382.65 | 257.03 |
Income Tax Expense | 70.48 | 89.9 | 95.99 | 45.4 | 35.37 | 30.69 |
Earnings From Continuing Operations | 354.73 | 376.24 | 412.27 | 190.33 | 347.28 | 226.34 |
Minority Interest in Earnings | 29.47 | 44.2 | 3.85 | -9.86 | 4.95 | 3.73 |
Net Income | 384.21 | 420.45 | 416.12 | 180.47 | 352.23 | 230.07 |
Net Income to Common | 384.21 | 420.45 | 416.12 | 180.47 | 352.23 | 230.07 |
Net Income Growth | -10.69% | 1.04% | 130.58% | -48.76% | 53.10% | -37.95% |
Shares Outstanding (Basic) | 232 | 233 | 237 | 340 | 345 | 347 |
Shares Outstanding (Diluted) | 232 | 233 | 237 | 340 | 345 | 347 |
Shares Change (YoY) | 43.49% | -1.77% | -30.24% | -1.46% | -0.62% | 8.72% |
EPS (Basic) | 1.65 | 1.80 | 1.75 | 0.53 | 1.02 | 0.66 |
EPS (Diluted) | 1.65 | 1.80 | 1.75 | 0.53 | 1.02 | 0.66 |
EPS Growth | -37.76% | 2.86% | 230.53% | -48.01% | 54.06% | -42.93% |
Free Cash Flow | 375.77 | 284.39 | 368.85 | -77.91 | 71.41 | 72.38 |
Free Cash Flow Per Share | 1.62 | 1.22 | 1.55 | -0.23 | 0.21 | 0.21 |
Dividend Per Share | 1.000 | 1.000 | 0.510 | 0.286 | 0.500 | 0.357 |
Dividend Growth | 9.87% | 96.00% | 78.58% | -42.86% | 40.02% | -28.58% |
Gross Margin | 68.38% | 68.54% | 70.09% | 68.79% | 71.98% | 74.78% |
Operating Margin | 10.49% | 13.88% | 14.87% | 7.81% | 11.25% | 7.01% |
Profit Margin | 15.34% | 15.69% | 15.79% | 8.58% | 20.13% | 17.37% |
Free Cash Flow Margin | 15.01% | 10.61% | 14.00% | -3.70% | 4.08% | 5.46% |
EBITDA | 442.3 | 549.05 | 565.26 | 343 | 332.03 | 206.21 |
EBITDA Margin | 17.66% | 20.49% | 21.45% | 16.31% | 18.97% | 15.57% |
D&A For EBITDA | 179.7 | 177.03 | 173.47 | 178.62 | 135.13 | 113.38 |
EBIT | 262.6 | 372.03 | 391.79 | 164.38 | 196.9 | 92.83 |
EBIT Margin | 10.49% | 13.88% | 14.87% | 7.81% | 11.25% | 7.01% |
Effective Tax Rate | 16.57% | 19.29% | 18.89% | 19.26% | 9.24% | 11.94% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.